Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vatalanib
- Development stage
- Phase 3
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vatalanib is an orally bioavailable small molecule tyrosine kinase inhibitor developed as an antiangiogenic agent for cancer therapy. It selectively inhibits the tyrosine kinase domains of all known vascular endothelial growth factor (VEGF) receptors (VEGFR-1, VEGFR-2, and VEGFR-3), as well as platelet-derived growth factor (PDGF) receptor and c-KIT. By blocking these kinases, vatalanib disrupts angiogenesis—the formation of new blood vessels—which is critical for tumor growth and metastasis. Vatalanib has been investigated in combination with chemotherapy for metastatic colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, glioblastoma multiforme (GBM), melanoma, and other solid tumors[1][2][3][4][5].
- Brand names
- vatalanib
- Other names
- vatalanib basevatalinib
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on vatalanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vatalanib.